12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TD-4208: Phase IIb started

Theravance began a double-blind, crossover, New Zealand Phase IIb trial to evaluate once-daily 22, 44, 88, 175, 350 and 700 ug TD-4208 via a nebulizer in about 60 patients....

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >